[
  {
    "ts": null,
    "headline": "Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?",
    "summary": "VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.",
    "url": "https://finnhub.io/api/news?id=ee8e874f54af59abc42468be57d34b71576760ee8599915605a61a06b1947d17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770460,
      "headline": "Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?",
      "id": 137671217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.",
      "url": "https://finnhub.io/api/news?id=ee8e874f54af59abc42468be57d34b71576760ee8599915605a61a06b1947d17"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards",
    "summary": "Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied to a review of reported child fatalities following COVID 19 vaccinations. See our latest analysis for Moderna. That 6% drop sits on top of a steep year to date share price return of around negative 43%, and with one year total shareholder return also down sharply, it suggests sentiment is still fragile and recent momentum is fading despite episodic regulatory and...",
    "url": "https://finnhub.io/api/news?id=7aa3821e72a291431b36564f83a83715cc740d2dd7f5aff9c62fd27d7babd943",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764738665,
      "headline": "Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards",
      "id": 137668424,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied to a review of reported child fatalities following COVID 19 vaccinations. See our latest analysis for Moderna. That 6% drop sits on top of a steep year to date share price return of around negative 43%, and with one year total shareholder return also down sharply, it suggests sentiment is still fragile and recent momentum is fading despite episodic regulatory and...",
      "url": "https://finnhub.io/api/news?id=7aa3821e72a291431b36564f83a83715cc740d2dd7f5aff9c62fd27d7babd943"
    }
  }
]